ViaLase to Present New Clinical Data at ASCRS
ViaLase announced that it will present clinical data as well as provide a business and technology overview during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held April 5-8, 2024 in Boston, Massachusetts. ViaLase will be exhibiting onsite at booth #2417.
Presentations at Eyecelerator and ASCRS 2024 will provide insights into the company’s ViaLase Laser and 3-year outcomes of the first-in-human study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) treatment in patients with glaucoma. ViaLase recently announced that it had completed a Series C round of financing, which will fund continued advancement of clinical, regulatory, and commercial milestones for the ViaLase Laser.
“We are excited to share the latest clinical data demonstrating the safety and efficacy of the ViaLase technology, which incorporates a femtosecond laser and high definition imaging to perform the FLigHT treatment, with the ophthalmic community at ASCRS,” Tibor Juhasz, PhD, Founder and CEO, ViaLase, said in a company news release. “The ViaLase Laser has the potential to provide physicians with the first truly noninvasive, early-intervention option for patients with primary open angle glaucoma, and could fundamentally change the glaucoma treatment paradigm as we know it.”
The corporate and clinical presentations are scheduled as follows:
Title: Presenting Company Showcase (Breakout 2)– ViaLase Presentation
Date: Thursday, April 4, 2024
Time: 1:45 p.m. - 1:53 p.m. EDT
Location: Eyecelerator, Omni Boston Hotel at the Seaport
Presenter: Peter England, Vice President, Global Marketing, ViaLase● Title: Durable 36 Month IOP Reduction in Open Angle Glaucoma with Femtosecond
Laser Guided High Precision Trabeculotomy (FLigHT)
Date: Sunday, April 7, 2024
Time: 4:02 p.m. - 4:07 p.m EDT
Location: BCEC - Meeting Level 2, Room 259A
Presenter: Zoltan Z. Nagy, MD, PhD, FEBO, FACS
*The ViaLase Laser is not approved for use in the United States.